Interim Report to 30 September 2015 is now available to view via the following link. The PDF report will download automatically when clicked.
Access to AFT FY16 Interim Report
Similar articles
AFT licenses Maxigesic® IV in the US
AFT Pharmaceuticals announces it has signed an exclusive License and Distribution Agreement with Hikma Pharmaceuticals USA (“Hikma”) for the commercialisation of its Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine, in the United States.
Read more
AFT submits Maxigesic IV® packaging data to the US FDA
AFT Pharmaceuticals announces it has submitted to the US Food and Drug Administration (FDA) data the regulator requested, as it considers registration of the company’s patented intravenous pain relief medicine Maxigesic IV.
Read more
AFT appoints Andrew Lane as independent director
AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director.
Read more